Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Vidarabine Monohydrate: Applied Research Workflow
2026-09-13
Build more reproducible antiviral assays with Vidarabine monohydrate by controlling DMSO formulation, exposure timing, and orthogonal viral readouts. This workflow adapts a validated screening principle from a protein-interaction study without confusing its neuroscience mechanism with antiviral biology.
-
Ibuprofen: Applied Workflows for Cell Research
2026-09-12
Build reproducible Ibuprofen experiments around COX-1/COX-2 biology, apoptosis, and cell-cycle measurements rather than relying on viability alone. This practical guide also shows how albumin-binding concepts from a molecular recognition study can improve assay interpretation without overextending the evidence.
-
FXR–KLF11 Signaling in Contrast-Induced AKI
2026-09-11
The reference study identifies an FXR–KLF11 transcriptional pathway that suppresses JAK2/STAT3 signaling and protects against contrast-induced acute kidney injury in mouse and HK-2 cell models. Its combination of pharmacological treatment, genetic loss-of-function, RNA sequencing, reporter assays, and ChIP experiments provides a mechanistic framework for studying bile acid receptor signaling in renal injury.
-
Nano-Granulated Zoledronate Reprograms Immunity
2026-09-11
Chen et al. develop Nano-ZD, a lymph-node-directed zoledronate formulation that targets innate immune metabolism rather than bone tissue. The study links CoQ depletion with altered OXPHOS and pyrimidine metabolism, MAVS and inflammasome activation, and stronger vaccine and antitumor responses when combined with MPLA or αPD-L1.
-
Tiamulin (Thiamutilin) Assay Workflows
2026-09-10
Tiamulin (Thiamutilin) combines ribosome-targeted antibacterial activity with experimentally useful anti-inflammatory effects, making it valuable for pathogen susceptibility, cell-signaling, and veterinary pharmacology studies. This guide translates its binding biology into practical workflows, controls, and troubleshooting strategies for reproducible research.
-
hiPSC Intestinal Organoids for Pharmacokinetics
2026-09-10
Saito and colleagues developed a direct three-dimensional cluster-culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be propagated, cryopreserved, and differentiated into intestinal epithelial cells with enterocyte-associated metabolic and transporter activities, supporting their use in human-relevant pharmacokinetic studies.
-
NSC-23766: Rac GTPase Inhibitor Guide
2026-09-09
NSC-23766 is a selective Rac GTPase inhibitor that blocks Rac1 activation by Trio and Tiam1-related guanine nucleotide exchange factor interactions. Product and cell-study evidence supports its use in cancer research, endothelial-barrier assays, apoptosis studies, and mechanistic Rac1 signaling experiments.
-
Amikacin Sulfate: Applied Research Workflows
2026-09-09
Build reproducible Amikacin Sulfate workflows for planktonic, intracellular, and granuloma-focused infection models. This guide connects concentration-response testing with cellular uptake, targeted delivery, CFU measurement, and troubleshooting for Mycobacterium avium and Staphylococcus aureus research.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-08
Hannah Schwartz’s dissertation identifies a critical interpretive problem in cancer pharmacology: relative viability and fractional viability are often treated as interchangeable even though they capture different components of drug response. Its findings support time-resolved, orthogonal assays that distinguish proliferative arrest from true cell killing and improve the interpretation of in vitro drug sensitivity.
-
N1-Methylpseudo-UTP for mRNA Workflow
2026-09-08
Build more stable, translation-ready RNA with a workflow that connects modified-nucleotide in vitro transcription to antigen and adjuvant mRNA design. This guide shows how to control reagent handling, benchmark transcript performance, and translate LNP findings into practical assay choices without overstating what the reference study proves.
-
Tiamulin: An Evidence-Led Veterinary Assay Guide
2026-09-07
Tiamulin (Thiamutilin) is more than a veterinary antibiotic: its ribosomal pharmacology, exposure targets, inflammatory signaling, and ionophore interactions determine how experiments should be designed. This guide presents a conflict-aware framework for interpreting antibacterial and anti-inflammatory data.
-
Tivozanib AV-951: Smarter Cancer Response Assays
2026-09-07
Tivozanib (AV-951) is a selective VEGFR inhibitor whose value in oncology research depends on more than endpoint potency. This guide shows how to pair its mechanism with growth-inhibition and cell-killing measurements for more interpretable cancer assays.
-
α2-adrenergic receptor agonist: B3465
2026-09-05
This scenario-driven guide explains how SKU B3465, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine, can support reproducible α2-adrenergic receptor signaling and cell-based immune-modulation research. It covers solubility, CCK-8 assay design, interpretation of non-cytotoxic results, and practical product-selection criteria.
-
HSC70 Directs TGEV Entry via Clathrin Endocytosis
2026-09-04
Ji and colleagues identify HSC70 as a host factor that binds the TGEV membrane protein and promotes viral internalization through clathrin-mediated endocytosis. The study expands the functional scope of coronavirus M protein beyond assembly and suggests that HSC70 ATPase activity is relevant to an early entry step, while also defining experimental considerations for host-factor validation.
-
Nanoparticle RNAi Targets btCHS and btG6PI
2026-09-04
The 2026 study developed a C60/alkylpolyglucoside nanocarrier system to improve dsRNA delivery against the whitefly Bemisia tabaci. Compared with dsRNA alone, nanoparticle-associated dsRNA produced stronger target-gene silencing and lower insect survival, supporting nanocarriers as an important design element for plant-mediated RNAi pest control.